Core Insights - The article emphasizes the importance of investing in growth and momentum stocks that are reasonably priced and have the potential to outperform the market in the long term [1] - It highlights a successful investment strategy where the S&P 500 increased by 367% and the Nasdaq by 685% from March 2009 to 2019, indicating a strong recovery from the financial crisis [1] Investment Strategy - The focus is on long-term investment in high-quality growth stocks, with the use of options as part of the strategy [1] - The article suggests that investors should conduct their own research or consult financial advisers to determine suitable investments for their individual situations [3] Performance Metrics - The significant performance of the S&P 500 and Nasdaq over a decade serves as a benchmark for potential investment returns [1] - The article does not provide specific stock recommendations but emphasizes the historical performance as a guide for future investment considerations [4]

Core Insights - Emergent BioSolutions has secured exclusive commercial rights in the U.S. and Canada for Hikma Pharmaceuticals' KLOXXADO Nasal Spray, an 8 mg naloxone product aimed at treating opioid overdoses [1] - The agreement is part of Emergent's strategy to combat the opioid crisis by enhancing access to naloxone and increasing public awareness [1][2] - The company aims to provide two naloxone options: NARCAN Nasal Spray 4 mg and KLOXXADO Nasal Spray 8 mg, allowing for tailored treatment approaches [3][4] Company Strategy - Emergent's acquisition of KLOXXADO complements its existing product, NARCAN, and reinforces its commitment to reducing opioid overdose deaths [1][2] - The company emphasizes the importance of broadening public awareness and access to naloxone as a critical component in addressing the opioid epidemic [4][6] - KLOXXADO will be integrated into Emergent's NARCANDirect online distribution network, facilitating bulk purchases for emergency services and community organizations [4] Industry Context - The opioid overdose death rate in the U.S. saw a meaningful decline last year, marking the first significant decrease since 2018, attributed to various factors including increased naloxone access [2] - Emergent's dual product offering is positioned to meet the diverse needs of patients and communities affected by opioid overdoses [3][6] - The ongoing opioid crisis necessitates effective treatment options and public education to mitigate the impact of overdoses [4][6]

This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and procurement of Ebanga™, with a maximum value of $704 millionProgram progress and performance triggers $16.7 million contract option GAITHERSBURG, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of He ...

GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world​, today announced that Joe C. Papa, president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 1:30 PM PST. The audio link for Emergent's session may be accessed here and will be live for up to 30 days. The company’s slides will ...

GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense (DoD). The first delivery, which was valued at approximately $7 million began in December 2024, and remaining deliveries are expected in 2025. “We’re pleased to continue our work with the U.S. Department of Defense to supply BioThrax® to ...

Company Overview - Emergent BioSolutions (EBS) stock gained nearly 12% on the day following an analyst's initiation of coverage, contrasting with the S&P 500's 1% decline [2] - H C Wainwright's Raghuram Selvaraju initiated coverage with a buy recommendation and a price target of $15 per share, which is 62% higher than the stock's current level [3] - The company is well positioned to be a frontline player in potential future healthcare emergencies due to its diversified offerings [4][6] Business Segments - The company's vaccines business includes jabs for monkeypox and smallpox, with monkeypox recently highlighted as a potential global healthcare threat [1] - Emergent's Narcan opioid reversal spray is expected to continue experiencing heavy demand due to the ongoing opioid epidemic in the U S [5] Analyst Perspective - Raghuram Selvaraju views Emergent as well diversified across several medical segments with strong growth potential [5] - The analyst's positive outlook on the company's diversification makes the stock a worthy consideration for investment [6]

Shares of Emergent BioSolutions (EBS) have more than doubled in market cap so far this year, outperforming the industry’s 13% decline, as seen in the chart below. This surge in stock price started earlier this year after management announced several strategic changes to enhance profitability and stabilize its financial position. During the same period, the stock has also outperformed the broader Medical sector and the S&P 500. It is currently trading above its 200-day moving average.EBS Stock Outperforms In ...

GAITHERSBURG, Md., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Biomedical Advanced Research and Development Authority (BARDA) within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services has awarded a $50 million option to Emergent's existing contract (HHSO100201600030C) for the acquisition of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted). Deliveries are expected to begin this calendar yea ...

Emergent BioSolutions (EBS -5.59%) saw its shares tumble on Tuesday, due to news of a share sell-off. The vaccine maker divulged in a regulatory filing that several institutional share and warrant holders are selling such securities. Investors reacted by trading Emergent's stock down by almost 6%, on a day when the S&P 500 (^GSPC 0.05%) more or less flatlined.Unloading shares and exercising warrantsThe selling parties are mainly entities affiliated with OHA Agency, a business that provided a $250 million te ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Emergent BioSolutions (NYSE: EBS ), the Gaithersburg, Maryland headquartered biotech reported its Q3 earnings on Wednesday 6th November, after the bell, leading to a 20% su ...